PsychRounds: The Psychiatry Podcast

Welcome back! Today, we will be discussing the placebo effect.

References:
https://pubmed.ncbi.nlm.nih.gov/16503356/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003660/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556377/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714297/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694178/
https://www.psychiatrypodcast.com/psychiatry-psychotherapy-podcast/2018/11/19/understanding-placebo

Welcome back! Today we are talking all about Amantadine, and it's uses in psychiatry.

Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo).

References:
https://pubmed.ncbi.nlm.nih.gov/41626799/
https://www.ncbi.nlm.nih.gov/books/NBK548187/
https://pubmed.ncbi.nlm.nih.gov/41626799/

We are back with another special guest episode! Please welcome Dr. Allen Frances, who was intricately involved in the formation of both the DSM III and DSM IV, the latter of which he served as chair.

https://x.com/AllenFrancesMD
https://www.amazon.com/stores/author/B001HO76FU
https://www.psychiatrictimes.com/authors/allen-frances-md

Welcome back! Today we will be doing a brief episode on Topiramate [Topamax], and its clinical uses in psychiatry.

References:
https://pubmed.ncbi.nlm.nih.gov/21438989/

https://pubmed.ncbi.nlm.nih.gov/18774432/

https://pubmed.ncbi.nlm.nih.gov/25899459/

https://pmc.ncbi.nlm.nih.gov/articles/PMC1088011/

https://pmc.ncbi.nlm.nih.gov/articles/PMC2671954/

https://pubmed.ncbi.nlm.nih.gov/38706338/

https://pubmed.ncbi.nlm.nih.gov/20207521/